Published in Henry Ford Hosp Med J on January 01, 1989
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
Phylogenetic perspectives in innate immunity. Science (1999) 9.42
Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet (1991) 6.61
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet (2001) 5.08
The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med (1994) 4.65
Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc Natl Acad Sci U S A (1987) 3.98
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Activation and somatic mutation of the translocated c-myc gene in burkitt lymphoma cells. Cell (1984) 3.66
Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet (1996) 3.56
Transcriptional activation of an unrearranged and untranslocated c-myc oncogene by translocation of a C lambda locus in Burkitt. Proc Natl Acad Sci U S A (1983) 3.53
Macrophage complement and lectin-like receptors bind Leishmania in the absence of serum. J Exp Med (1985) 3.44
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26
The human mannose-binding protein functions as an opsonin. J Exp Med (1989) 3.15
CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet (2004) 3.03
Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J Virol (1991) 3.03
Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma. Nature (1982) 3.03
West Nile virus: an overview of its spread in Europe and the Mediterranean basin in contrast to its spread in the Americas. Eur J Clin Microbiol Infect Dis (2004) 3.00
Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest (1994) 2.97
Surface properties of bacillus Calmette-Guérin-activated mouse macrophages. Reduced expression of mannose-specific endocytosis, Fc receptors, and antigen F4/80 accompanies induction of Ia. J Exp Med (1981) 2.89
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet (2000) 2.77
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer (2007) 2.62
Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol (1990) 2.58
Local opsonization by secreted macrophage complement components. Role of receptors for complement in uptake of zymosan. J Exp Med (1984) 2.53
Histoprognostic grade in BRCA1-associated breast cancer. Lancet (1995) 2.47
Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol (2001) 2.41
Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med (2000) 2.39
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet (1999) 2.36
Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer (1996) 2.33
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst (1998) 2.33
The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol (1998) 2.31
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet (2000) 2.31
Croquemort, a novel Drosophila hemocyte/macrophage receptor that recognizes apoptotic cells. Immunity (1996) 2.30
Requirement for croquemort in phagocytosis of apoptotic cells in Drosophila. Science (1999) 2.29
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat (2008) 2.27
Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet (1997) 2.15
The impact of family history on early detection of prostate cancer. Nat Med (1995) 2.14
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet (1999) 2.14
Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics (1999) 2.12
Geographical prevalence of two types of Epstein-Barr virus. Virology (1986) 2.05
BRCA1 and BRCA2 mutations and the risk for colorectal cancer. Clin Genet (2014) 2.02
A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol (2001) 2.01
A polymorphic stop codon in BRCA2. Nat Genet (1996) 1.95
Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr (1998) 1.95
On being the right size: a reappraisal of mammography trials in Canada and Sweden. Lancet (1997) 1.94
DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study. Arch Intern Med (1993) 1.91
An estimate of the heritable fraction of childhood cancer. Br J Cancer (1991) 1.89
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet (1998) 1.88
Cancer genetics clinics: target population and consultees' expectations. Eur J Cancer (1996) 1.88
Interaction of human monocytes, macrophages, and polymorphonuclear leukocytes with zymosan in vitro. Role of type 3 complement receptors and macrophage-derived complement. J Clin Invest (1985) 1.86
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res (2001) 1.81
Human mannose-binding protein functions as an opsonin for influenza A viruses. J Clin Invest (1993) 1.80
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet (1998) 1.77
Aberrant c-myc RNAs of Burkitt's lymphoma cells have longer half-lives. EMBO J (1985) 1.76
A variant translocation places the lambda immunoglobulin genes 3' to the c-myc oncogene in Burkitt's lymphoma. Nature (1984) 1.75
A novel alteration in the structure of an activated c-myc gene in a variant t(2;8) Burkitt lymphoma. Cell (1984) 1.74
The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt's lymphoma. IARC Sci Publ (1985) 1.73
Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet (2005) 1.71
Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet (2001) 1.68
A breast-ovarian cancer susceptibility gene maps to chromosome 17q21. Am J Hum Genet (1993) 1.66
Distinct and overlapping functions of allelic forms of human mannose binding protein. Nat Genet (1992) 1.66
Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12). Cancer Genet Cytogenet (1984) 1.65
Identification of the coding region for a second Epstein-Barr virus nuclear antigen (EBNA 2) by transfection of cloned DNA fragments. EMBO J (1985) 1.65
The human mannose-binding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. J Exp Med (1989) 1.64
Macrophage activation selectively enhances expression of Fc receptors for IgG2a. J Exp Med (1983) 1.63
Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int J Cancer (1985) 1.62
Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma. Int J Cancer (1986) 1.62
Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest (1998) 1.61
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61
Down-regulation of mannosyl receptor-mediated endocytosis and antigen F4/80 in bacillus Calmette-Guérin-activated mouse macrophages. Role of T lymphocytes and lymphokines. J Exp Med (1982) 1.61
Role of macrophage oxidative burst in the action of anthrax lethal toxin. Mol Med (1994) 1.60
The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Semin Immunol (1998) 1.60
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res (2000) 1.57
Non-random transmission of mutant alleles to female offspring of BRCA1 carriers in Poland. J Med Genet (2003) 1.57
Identification of Epstein-Barr virus terminal protein 1 (TP1) in extracts of four lymphoid cell lines, expression in insect cells, and detection of antibodies in human sera. J Virol (1990) 1.56
Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet (1997) 1.55
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology (2001) 1.54
An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation? Am J Hum Genet (1999) 1.52
In-situ breast cancer and BRCA1. Lancet (1996) 1.52
Drosophila scavenger receptor CI is a pattern recognition receptor for bacteria. Immunity (2001) 1.52
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2011) 1.51
Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A. In Vitro Cell Dev Biol (1986) 1.51
Collectins: pattern recognition molecules involved in first line host defense. Curr Opin Immunol (1993) 1.50
A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res (1997) 1.49
Human mannose-binding protein activates the alternative complement pathway and enhances serum bactericidal activity on a mannose-rich isolate of Salmonella. J Clin Invest (1989) 1.47
Induction of phagocyte cytochrome b heavy chain gene expression by interferon gamma. Proc Natl Acad Sci U S A (1988) 1.47
The collectins in innate immunity. Curr Opin Immunol (1996) 1.46
PTEN germ-line mutations in juvenile polyposis coli. Nat Genet (1998) 1.45
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet (1996) 1.45
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat (2007) 1.44